Improving HIV-1 Control in Africa With Long Acting Antiretrovirals
Status:
Not yet recruiting
Trial end date:
2025-11-01
Target enrollment:
Participant gender:
Summary
IMPALA is a randomized, open-label, multicenter, interventional study of 540 virologically
suppressed HIV-1 infected adults who have a history of, or are at high risk of, sub-optimal
adherence to daily oral ART and/or engagement in HIV care. The study will seek to demonstrate
non-inferior antiviral effectiveness of the 2-monthly long-acting injectable combination of
cabotegravir/rilpivirine as compared to continuation of first line oral antiretroviral
therapy.